Document 1203
 DOCN  M9591203
 TI    Tat-induced lesions in transgenic mice do not correlate with the HIV-1
       LTR transactivation.
 DT    9509
 AU    Fergelot P; Molina T; Blanchet P; Grimber G; Duquenne O; Couton D; Zider
       A; Briand P; Cavard C; Laboratoire de genetique et pathologie
       experimentales, INSERM; U 380, Institut Cochin de genetique moleculaire,
       Paris,; France.
 SO    C R Acad Sci III. 1995 Mar;318(3):329-37. Unique Identifier : AIDSLINE
       MED/95308298
 AB    The product of the tat gene is the most potent transcriptional
       trans-activator of the HIV-1 LTR (Human Immunodeficiency Virus type 1
       Long Terminal Repeat) and might be predicted to be one of the HIV-1
       proteins involved in the pathogenesis of AIDS-associated tumors.
       Deciphering its role in vivo may imply generation of transgenic mouse
       models displaying different spectra of tat expression. However, it
       remains difficult to correlate the mRNA expression, the protein
       production and the eventual pathological consequences in the animal. Our
       goal in this work was to elaborate a binary transgenic system allowing
       such an approach, the correlation of the transgene expression in
       different tissues and the production of the Tat protein, tested as a
       trans-activator in vivo, with its pathogenic effects. No direct linkage
       was evident between the degree of transactivation and pathogenesis.
       Indeed, only benign lesions were observed in malpighian epithelia, where
       the production of the Tat protein was clearly evidenced by its
       transactivating property.
 DE    Animal  Epithelium/INJURIES  Gene Products, tat/*GENETICS/METABOLISM
       Genes, tat/GENETICS  HIV-1/*GENETICS  Malpighian Tubules/ULTRASTRUCTURE
       Mice  Mice, Transgenic  Support, Non-U.S. Gov't  Trans-Activation
       (Genetics)  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).